Overall, 40% of patients had metastatic cancer, 83% had completed chemotherapy within 6 months of enrollment, 75% had received their last G-CSF treatment within 6 months of enrollment, and 48% had received pegfilgrastim for febrile neutropenia prophylaxis. Here, CSF3 is linked to metastatic malignant neoplasm.